ENALAPRIL AFTER ANTHRACYCLINE CARDIOTOXICITY

这种随机、双盲安慰剂的主要目的是 对照试验是为了确定长期给药是否 血管紧张素转换酶抑制剂依那普利的使用量将会下降 蒽环类药物所致心功能不全的发生率 没有明显的充血性心力衰竭。所有患者都必须有 记录的继发于嗜人环素的心脏异常 治疗儿童恶性肿瘤，并接受过两次以上的治疗 几年前。

The primary objective of this randomized, double-blinded placebo controlled trial is to determine whether the long-term administration of enalapril, an angiotensin converting enzyme inhibitor, will decrease the rate of anthracycline-induced cardiac dysfunction in patients without overt congestive heart failure. All patients must have documented cardiac abnormalities secondary to anthrocyclines used for treating pediatric malignancies and have received therapy more than two years ago.